ahlam1399
07-31-2015, 08:49 PM
After Merck success, work goes on with other Ebola vaccines
LONDON, July 31 (Reuters) - Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics proving 100 percent effective in a trial in Guinea.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/489aeba3/sc/7/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=o76r61y3rAA:cNMu6znvarU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=o76r61y3rAA:cNMu6znvarU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=o76r61y3rAA:cNMu6znvarU:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=o76r61y3rAA:cNMu6znvarU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=o76r61y3rAA:cNMu6znvarU:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/o76r61y3rAA
LONDON, July 31 (Reuters) - Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics proving 100 percent effective in a trial in Guinea.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/489aeba3/sc/7/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=o76r61y3rAA:cNMu6znvarU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=o76r61y3rAA:cNMu6znvarU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=o76r61y3rAA:cNMu6znvarU:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=o76r61y3rAA:cNMu6znvarU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=o76r61y3rAA:cNMu6znvarU:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/o76r61y3rAA